Copyright
©The Author(s) 2020.
World J Gastrointest Pharmacol Ther. Jun 9, 2020; 11(2): 25-39
Published online Jun 9, 2020. doi: 10.4292/wjgpt.v11.i2.25
Published online Jun 9, 2020. doi: 10.4292/wjgpt.v11.i2.25
Feature | Level | Total cohort | Subcohort | ||
Invasive IPMN | Non-IPMN associated PDAC | P value | |||
Median (IQR) | |||||
Age (in yr) | 67.6 (60.0, 74.8) | 70.0 (64.1, 75.5) | 66.7 (59.4, 74.0) | 0.003 | |
Tumor size (in cm) | 3.5 (2.5, 5.0) | 3.0 (2.0, 4.5) | 3.6 (2.5, 5.2) | 0.012 | |
Median (95%CI) | |||||
PFS (in mo) | 21.0 (17.0, 27.0) | NR (47.0, NR) | 17.0 (13.0, 22.0) | < 0.001 | |
OS (in mo) | 21.0 (19.0, 24.0) | 60.0 (28.0, 69.0) | 19.0 (18.0, 22.0) | < 0.001 | |
n (%) | |||||
Gender (male/female) | Female | 243 (53.5) | 61 (53.0) | 182 (53.7) | 0.991 |
Male | 211 (46.5) | 54 (47.0) | 157 (46.3) | ||
Tumor differentiation | Well | 41 (9.0) | 15 (13.4) | 26 (7.9) | 0.103 |
Moderate | 271 (59.7) | 71 (63.4) | 200 (61.0) | ||
Poor | 128 (28.2) | 26 (23.2) | 102 (31.1) | ||
AJCC 8th ed staging system | T1 | 76 (16.7) | 32 (27.8) | 44 (13.0) | 0.003 |
T2 | 202 (44.5) | 46 (40.0) | 156 (46.2) | ||
T3 | 166 (36.6) | 36 (31.3) | 130 (38.5) | ||
AJCC 8th ed staging system | N0 | 216 (47.6) | 69 (60.0) | 147 (43.4) | 0.004 |
N1 | 181 (39.9) | 31 (27.0) | 150 (44.2) | ||
N2 | 57 (12.6) | 15 (13.0) | 42 (12.4) | ||
Lymphovascular invasion | Positive | 219 (48.2) | 44 (38.3) | 175 (51.6) | 0.011 |
Negative | 219 (48.2) | 69 (60.0) | 150 (44.2) | ||
Indetermi-nant | 16 (3.5) | 2 (1.7) | 14 (4.1) | ||
Perineural invasion | Positive | 366 (80.6) | 80 (69.6) | 286 (84.4) | 0.001 |
Negative | 82 (18.1) | 34 (29.6) | 48 (14.2) | ||
Indetermi-nant | 6 (1.3) | 1 (0.9) | 5 (1.5) | ||
Recurrence/metastasis | Present | 218 (48.0) | 43 (37.4) | 175 (51.6) | 0.015 |
Absent | 236 (52.0) | 72 (62.6) | 164 (48.4) | ||
Splenic parenchymal invasion | Present | 25 (5.5) | 2 (1.7) | 23 (6.9) | 0.067 |
Absent | 425 (93.6) | 113 (98.3) | 312 (93.1) |
Feature | Level | PFS | OS | ||
HR (95%CI), P value | |||||
Gender | 1.67 (0.91-3.05), P = 0.10 | - | 1.33 (0.85-2.08), P = 0.22 | - | |
Age | 0.99 (0.96-1.02), P = 0.52 | - | 1.01 (0.98-1.03), P = 0.54 | - | |
Tumor size | 1.18 (1.05-1.32), P = 0.01 | - | 1.10 (1.00-1.21), P = 0.04 | - | |
Tumor differentiation | Well | - | - | - | - |
Moderate | 2.71 (0.82-8.91), P = 0.10 | 12290265.82 (0.00-Inf), P = 1.00 | 1.04 (0.53-2.02), P = 0.92 | 1.62 (0.34-7.66), P = 0.55 | |
Poor | 3.88 (1.06-14.27), P = 0.04 | 2274054.50 (0.00-Inf), P = 1.00 | 2.31 (1.10-4.86), P = 0.03 | 1.78 (0.15-20.67), P = 0.64 | |
Positive lymph node | 1.19 (1.05-1.35), P = 0.01 | - | 1.19 (1.07-1.31), P < 0.01 | - | |
T stage (AJCC 8th edition staging manual) | T1 | - | - | - | - |
T2 | 2.69 (1.14-6.37), P = 0.02 | 0.81 (0.07-9.31), P = 0.87 | 1.65 (0.92-2.97), P = 0.09 | 0.89 (0.09-8.48), P = 0.92 | |
T3 | 3.48 (1.42-8.51), P = 0.01 | 5.29 (0.44-62.97), P = 0.19 | 2.28 (1.23-4.24), P = 0.01 | 26.22 (2.13-322.77), P = 0.01 | |
N stage (AJCC 8th edition staging manual) | N0 | - | - | - | - |
N1 | 2.03 (1.03-4.02), P = 0.04 | 13.78 (1.15-165.63), P = 0.04 | 1.58 (0.93-2.67), P = 0.09 | 1.17 (0.24-5.70), P = 0.85 | |
N2 | 3.65 (1.60-8.34), P < 0.01 | 29.12 (0.87-979.78), P = 0.06 | 2.52 (1.36-4.65), P < 0.01 | 1.63 (0.10-27.11), P = 0.73 | |
Lymphovascular invasion | 2.12 (1.16-3.90), P = 0.02 | 0.31 (0.04-2.41), P = 0.26 | 1.43 (0.90-2.28), P = 0.13 | - | |
Perineural invasion | 1.99 (0.98-4.04), P = 0.06 | - | 2.45 (1.39-4.33), P < 0.01 | 2.67 (0.54-13.22), P = 0.23 | |
Splenic artery invasion | 5.30 (1.41-19.94), P = 0.01 | 2.44 (0.10-62.16), P = 0.59 | 1.70 (0.59-4.88), P = 0.32 | - | |
Splenic vein invasion | 18.69 (4.57-76.48), P < 0.01 | 5.28 (0.22-129.25), P = 0.31 | 2.66 (1.08-6.55), P = 0.03 | 5.62 (0.61-51.99), P = 0.13 | |
Positive margin | 1.25 (0.30-5.19), P = 0.76 | - | 3.14 (1.49-6.62), P < 0.01 | 0.00 (0.00-Inf), P = 1.00 | |
Splenic parenchyma invasion | 14.93 (1.83-121.81), P = 0.01 | 1.00 (1.00-1.00), P = NaN | 1.23 (0.17-8.87), P = 0.84 | - | |
Adjuvant radiation therapy | 0.97 (0.52-1.81), P = 0.92 | - | 0.81 (0.48-1.37), P = 0.43 | - | |
Adjuvant chemotherapy | 2.50 (0.89-7.00), P = 0.08 | - | 0.69 (0.39-1.22), P = 0.20 | - | |
Radiographic splenic artery invasion | 2.12 (0.85-5.29), P = 0.11 | - | 1.45 (0.59-3.56), P = 0.41 | - | |
Radiographic splenic vein invasion | 2.27 (1.04-4.94), P = 0.04 | 2.88 (0.33-24.96), P = 0.34 | 1.46 (0.68-3.13), P = 0.33 | - |
Feature | Level | PFS | OS | ||
HR (95%CI), P value | |||||
Gender | 0.89 (0.66-1.20), P = 0.43 | - | 1.05 (0.82-1.35), P = 0.69 | - | |
Age | 0.99 (0.98-1.01), P = 0.29 | - | 1.01 (1.00-1.03), P = 0.05 | 1.00 (0.98-1.02), P = 0.93 | |
Tumor size | 1.07 (0.99-1.15), P = 0.09 | - | 1.08 (1.02-1.16), P = 0.01 | - | |
Tumor differentiation | Well | - | - | - | - |
Moderate | 1.11 (0.64-1.91), P = 0.71 | - | 1.33 (0.78-2.27), P = 0.29 | 1.56 (0.65-3.78), P = 0.32 | |
Poor | 1.21 (0.68-2.14), P = 0.52 | - | 1.72 (0.99-2.98), P = 0.05 | 2.23 (0.90-5.53), P = 0.08 | |
Positive lymph node | 1.06 (1.01-1.12), P = 0.03 | - | 1.08 (1.03-1.13), P < 0.01 | - | |
T stage (AJCC 8th edition staging manual) | T1 | - | - | - | - |
T2 | 1.39 (0.83-2.31), P = 0.21 | 1.22 (0.73-2.05), P = 0.45 | 0.97 (0.64-1.46), P = 0.87 | 1.12 (0.57-2.20), P = 0.73 | |
T3 | 1.56 (0.92-2.62), P = 0.10 | 1.19 (0.68-2.07), P = 0.54 | 1.33 (0.88-2.03), P = 0.18 | 0.80 (0.39-1.64), P = 0.54 | |
N stage (AJCC 8th edition staging manual) | N0 | - | - | - | - |
N1 | 1.73 (1.25-2.39), P < 0.01 | 1.59 (1.09-2.32), P = 0.02 | 1.75 (1.33-2.32), P < 0.01 | 2.54 (1.41-4.58), P < 0.01 | |
N2 | 1.57 (0.96-2.56), P = 0.07 | 1.47 (0.82-2.63), P = 0.20 | 1.83 (1.23-2.72), P < 0.01 | 2.45 (0.92-6.51), P = 0.07 | |
Lymphovascular invasion | 1.43 (1.05-1.95), P = 0.02 | 1.07 (0.73-1.56), P = 0.74 | 1.46 (1.12-1.89), P < 0.01 | 0.82 (0.45-1.49), P = 0.51 | |
Perineural invasion | 1.16 (0.76-1.78), P = 0.48 | - | 1.19 (0.83-1.73), P = 0.35 | - | |
Splenic artery invasion | 1.41 (0.71-2.80), P = 0.33 | - | 1.38 (0.81-2.36), P = 0.24 | - | |
Splenic vein invasion | 1.35 (0.82-2.23), P = 0.24 | - | 2.09 (1.44-3.03), P < 0.01 | 1.59 (0.83-3.02), P = 0.16 | |
Positive margin | 0.78 (0.43-1.40), P = 0.40 | - | 1.20 (0.78-1.82), P = 0.41 | - | |
Splenic invasion | 1.65 (0.95-2.85), P = 0.07 | - | 1.32 (0.82-2.11), P = 0.25 | - | |
Adjuvant radiation therapy | 0.93 (0.69-1.27), P = 0.66 | - | 0.85 (0.64-1.12), P = 0.25 | - | |
Adjuvant chemotherapy | 1.45 (0.90-2.34), P = 0.13 | - | 0.51 (0.37-0.71), P < 0.01 | 0.34 (0.20-0.58), P < 0.01 | |
Radiographic splenic artery invasion | 1.27 (0.87-1.84), P = 0.21 | - | 1.13 (0.81-1.59), P = 0.47 | - | |
Radiographic splenic vein invasion | 1.26 (0.88-1.80), P = 0.20 | - | 1.51 (1.10-2.07), P = 0.01 | 1.08 (0.65-1.80), P = 0.75 |
- Citation: Yin F, Saad M, Xie H, Lin J, Jackson CR, Ren B, Lawson C, Karamchandani DM, Bernabeu BQ, Jiang W, Dhir T, Zheng R, Schultz CW, Zhang D, Thomas CL, Zhang X, Lai J, Schild M, Zhang X, Liu X. Validation of American Joint Committee on Cancer 8th edition of TNM staging in resected distal pancreatic cancer. World J Gastrointest Pharmacol Ther 2020; 11(2): 25-39
- URL: https://www.wjgnet.com/2150-5349/full/v11/i2/25.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v11.i2.25